Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness

Mark Saunders,Muntzer Mughal,Brian R Davidson,Tim Mould,Omer Aziz,Sarah O'Dwyer,Kurinchi Gurusamy,Claire L Vale,Elena Pizzo,R Bhanot

doi:10.1136/bmjopen-2020-039314

Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness

Mark Saunders, Muntzer Mughal + Show 8 more

Open Access

https://doi.org/10.1136/bmjopen-2020-039314

Copy DOI

Journal: BMJ Open	Publication Date: May 1, 2020
Citations: 6	License type: open-access

Affiliation: The Christie NHS Foundation Trust, University College London, University College London Hospitals NHS Foundation Trust, Royal Free London NHS Foundation Trust, MRC Clinical Trials Unit

#Hyperthermic Intraoperative Peritoneal Chemotherapy #Individual Participant Data + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionThere is uncertainty about whether cytoreductive surgery (CRS)+hyperthermic intraoperative peritoneal chemotherapy (HIPEC) improves survival and/or quality of life compared with standard of care (SoC) in people with peritoneal metastases who...

Full Text